Sascha Schuermann/Getty Images News
- Baird has downgraded Qiagen (NYSE:QGEN) and Bio-Techne (NASDAQ:TECH) from overweight to neutral, citing concerns over NIH funding and the amount of revenue the companies receive from that agency.
- The investment bank cut its price target for Qiagen to $42 from $52 (~5% upside based